The EDC3 Knockout Huh-7 Polyclonal Cells product consists of a CRISPR/Cas9-edited polyclonal knockout cell population originating from the Huh-7 human hepatocellular carcinoma cell line. This product provides a pool of cells with targeted disruptions in the EDC3 gene, which encodes the enhancer of mRNA decapping 3 (EDC3) protein. The polyclonal format offers a biologically representative mix of edited cells, each carrying unique gene modifications, and is suitable for functional studies where clonal homogeneity is not required. By disabling EDC3 function, this knockout model serves as a tool for investigating mRNA decay and post-transcriptional gene regulation in a hepatic cellular context.
Huh-7 is a well-established adherent epithelial cell line derived from a 57-year-old Japanese male with well-differentiated hepatocellular carcinoma. These cells retain many differentiated liver functions and are extensively used to study hepatic gene expression, viral hepatitis infection, drug metabolism, and hepatotoxicity. The liver-specific background provides a physiologically relevant platform for exploring the intersection of mRNA surveillance pathways and hepatic pathology, including hepatocellular carcinoma. The EDC3 knockout in Huh-7 cells therefore permits the dissection of mRNA degradation mechanisms within a liver-derived model system.
EDC3 functions as a critical scaffold protein that enhances the activity of the decapping complex formed by DCP1A and DCP2, thereby accelerating removal of the 5?? m7G cap from mRNA transcripts. This decapping step commits mRNAs to exonucleolytic degradation by XRN1, triggering rapid transcript turnover. EDC3 also interacts with the LSM1-7 complex, DDX6, PATL1, and GW182, contributing to cytoplasmic P-body assembly. Upstream signals, including cellular stress and RNA-binding proteins such as tristetraprolin (TTP), modulate EDC3 activity. Through these interactions, EDC3 exerts post-transcriptional control over target mRNAs, coordinating gene expression programs.
In hepatocellular carcinoma, dysregulation of mRNA decay pathways can alter expression of oncogenes and tumor suppressors. The EDC3 knockout Huh-7 model enables interrogation of how loss of EDC3-dependent decapping impacts the hepatic transcriptome and P-body dynamics. EDC3 mutations are linked to neurodevelopmental disorders such as intellectual disability, making this system a platform to study cellular consequences of impaired mRNA surveillance. The Huh-7 background further supports studies in liver biology and drug metabolism.
Typical applications include measuring mRNA half-lives by RT-qPCR or metabolic labeling, profiling transcriptome-wide changes via RNA-seq, and visualizing P-bodies by immunofluorescence. Co-immunoprecipitation can map EDC3 interactors, and western blotting confirms knockout efficiency. These polyclonal cells are suitable for comparative studies of mRNA decay kinetics and decapping inhibition effects on liver cancer gene expression. For further technical details or to inquire about custom options, please contact Ascent Research.
